Form 8-K - Current report:
SEC Accession No. 0001641172-25-009952
Filing Date
2025-05-13
Accepted
2025-05-13 16:16:15
Documents
15
Period of Report
2025-05-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 33449
2 EX-99.1 ex99-1.htm EX-99.1 32114
3 GRAPHIC ex99-1_001.jpg GRAPHIC 3637
  Complete submission text file 0001641172-25-009952.txt   254971

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE aneb-20250513.xsd EX-101.SCH 3011
5 XBRL LABEL FILE aneb-20250513_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE aneb-20250513_pre.xml EX-101.PRE 22356
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3952
Mailing Address C/O ANEBULO PHARMACEUTICALS, INC. 1017 RANCH ROAD 620 SOUTH, SUITE 107 LAKEWAY TX 78734
Business Address C/O ANEBULO PHARMACEUTICALS, INC. 1017 RANCH ROAD 620 SOUTH, SUITE 107 LAKEWAY TX 78734 737 203 5270
Anebulo Pharmaceuticals, Inc. (Filer) CIK: 0001815974 (see all company filings)

EIN.: 851170950 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-40388 | Film No.: 25940356
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)